Induction of Antinuclear Antibody after Interferon Therapy in Patients with Type-C Chronic Hepatitis: Its Relation to the Efficacy of Therapy
Authors:
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 31 (7) , 716-722
Abstract
Background: The prevalence of antinuclear antibody (ANA) and interferon (IFN)-induced ANA has been documented in patients with chronic hepatitis C. In the present study we evaluated whether the induction pattern of ANA after IFN therapy is related to the efficacy of IFN therapy. Methods: Forty-four patients with chronic hepatitis C were enrolled. Autoimmune hepatitis was excluded in all. ANA was measured every month before, during, and for 6 months after IFN therapy (total dose, 336 ∼ 480 M units). Results: Eight of the 44 (18%) patients were positive for ANA before IFN therapy (group I). In group I six of the eight ANA-positive patients showed an increase in ANA titers during the therapy. Twenty-two of 36 (61%) ANA-negative patients turned positive for ANA, with titers of 1:80 or less during IFN therapy (group II). In 14 of the 36 (39%) ANA-negative patients ANA remained negative throughout the therapy (group III). The rates of sustained responders with a negativity of serum hepatitis C virus RNA and with normal alanine aminotransferase levels for at least 6 months after the cessation of therapy in groups I, II, and III were 25%, 23%, and 21%, respectively, giving no significant difference in the efficacy of therapy. No serious side effect was observed during the therapy. Conclusions: Administration of IFN frequently produced an induction of ANA or an increase in its titer, which did not affect the efficacy of IFN therapy.Keywords
This publication has 28 references indexed in Scilit:
- Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitisDigestive Diseases and Sciences, 1993
- Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.Gut, 1993
- Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.Gut, 1992
- Autoantibodies during α‐interferon therapy for chronic hepatitis BJournal of Medical Virology, 1991
- Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune processThe Lancet, 1990
- Autoantibodies and response to α-interferon in patients with chronic viral hepatitisJournal of Hepatology, 1990
- Type 2 autoimmune hepatitis and hepatitis C virus infectionThe Lancet, 1990
- HAZARDS OF INTERFERON THERAPY FOR HBV-SERONEGATIVE CHRONIC HEPATITISThe Lancet, 1989
- Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitisHepatology, 1989
- Review: Interferons and AutoimmunityThe American Journal of the Medical Sciences, 1988